Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Scientists probe epigenetic secrets behind apple and pear body shapes

NCT ID NCT02728635

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how genes and fat cells differ in people with apple-shaped (belly fat) versus pear-shaped (hip and thigh fat) bodies. Researchers will use body scans and fat biopsies from 27 healthy adults to compare fat tissue at the molecular level. The goal is to better understand why fat distribution varies, which could lead to improved obesity treatments in the future.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this research could help explain why people store fat in different places, potentially pointing toward new ways to treat obesity-related health issues.
What could go wrong
This is a small, early-stage observational study with only 27 participants, so findings may not apply broadly. It is not testing a treatment, so no direct health benefits are expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

27 people

The number who actually took part.

Started

Jul 2016

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 45 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18-45 years inclusive; * BMI 23-35 kg/m2 inclusive; * HbA1C \<6.0%; * Weight stable (± 3 kg) during the 3 months prior to enrollment; * Women must be \> 9 months post-partum; * Able to provide written, informed consent. Exclusion Criteria: * Postmenopausal women * Women with an oophorectomy * Fasting plasma glucose \> 126 mg/dL, or diagnosis with Type 2 Diabetes (T2DM) * Untreated or symptomatic thyroid disease. * Aminotransferase or aspartate aminotransferase \> 3x upper limit of laboratory reference range, or known diagnosis of liver disease. * Creatinine \> 2x upper limit of laboratory reference range, or known diagnosis of kidney disease. * Uncontrolled hypertension (BP \> 140 systolic or \> 90 diastolic) * New onset (\<3 months on a stable regime) use of oral contraceptives or hormone replacement therapy. * History of drug or alcohol abuse (\> 3 drinks per day) within the last 5 years, or psychiatric disease prohibiting adherence to study protocol. Current drug use may be determine by plasma or urine drug screens. * History of cancer within the last 5 years (skin cancers, with the exception of melanoma, may be acceptable). * History of organ transplant. * Myocardial Infarction within the last 6 months. * Current treatment with blood thinners or antiplatelet medications that cannot be safely stopped for biopsy and testing procedures. * History of HIV, active Hepatitis B or C or tuberculosis * Presence of clinically significant abnormalities on EKG. * Current smokers (smoking within the past 3 months). * Use of any medications known to influence glucose, fat and/or energy metabolism within the last 3 months (eg. growth hormone therapy, glucocorticoids \[steroids\], etc.) * Other chronic or acute illness that might affect study results / interpretation in the opinion of the clinical * Other items related to procedural risk (outlined below) such as bleeding disorder, claustrophobia, etc. * Elevated high sensitivity c-reactive protein or known active infection. * There are some implants which are MR compatible (safe) but would cause artifacts which could obscure our ability to measure an organ, e.g. full braces may negate the ability to measure brain size.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Translational Research Institute for Metabolism and Diabetes

    Orlando, Florida, 32804, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.